Agilon beats, raises outlook on risk-adjustment upside

 

Agilon Health beats Q1 2026 estimates and raises 2026 revenue and EBITDA outlook on risk-adjustment upside

• Q1 2026 revenue $1.42B (-7% YoY), net income $49M and adjusted EBITDA $54M reported for the quarter.
• Non-GAAP EPS $1.80 increased 146% YoY in Q1 2026 financial results.
• Q1 beat internal guidance on revenue, medical margin, and EBITDA, driven by risk-adjustment uplift.
• 2026 revenue guidance raised to $5.68-$5.81B with higher medical margin and EBITDA outlook, signaling confidence in improved data and contracting.
• Membership declined due to market and payer exits as company prioritizes profitability over growth.
• Medical cost trend remains elevated and Part D exposure/reserving still introduces earnings uncertainty.
• AI-enabled clinical pathways, especially heart failure, are showing tangible utilization and quality improvements.
• ACO REACH delivered strong Q1 EBITDA aided by one-time CMS fraud-related benchmark adjustment.
• Enhanced data pipeline supports higher estimated risk scores, improving visibility and predictability of results.
• Payer contracting for 2026 added meaningful rate benefit, while 2027 talks focused on margin protection.
• Main concern: Sustainability of margin improvement amid elevated cost trends and ongoing Part D and policy risk.
• Strong quarter, driven by higher risk-adjustment revenue, favorable medical cost development, and disciplined contracting.

https://finviz.com/quote?t=AGL&p=d